Number of shares and votes in Orexo

Uppsala, Sweden – July 31, 2014 - The number of shares and votes in Orexo AB has
changed as a result of the exercise of warrants in connection with the company’s
incentive programs.

Today, the last trading day of the month, there are in total 32,953,233 shares
and votes in the company.

For further information, please contact:
Henrik Juuel, EVP and Chief Financial Officer
Tel: +46 (0)18-780 88 00, E-mail: ir@orexo.com

About Orexo
Orexo is a specialty pharma company with commercial operations in the United
States and R&D in Sweden developing improved treatments using proprietary drug
delivery technology and commercial operations in the United States. The company
is commercializing its proprietary product, ZUBSOLV® sublingual tablets, for
maintenance treatment of opioid dependence, in the United States. The ZUBSOLV®
sublingual tablet is a novel formulation of buprenorphine and naloxone using
Orexo’s extensive knowledge in sublingual technologies. Orexo has a portfolio of
two approved and revenue generating products currently marketed under license in
the US, EU and Japan. Orexo AB, with its headquarters in Sweden, is listed on
NASDAQ OMX Stockholm Exchange and its American Depositary Receipts (ADRs) trade
on the OTCQX marketplace in the U.S. under the symbol, “ORXOY”. The largest
shareholders are Novo A/S and HealthCap.

For information about Orexo please visit www.orexo.com

Orexo AB (publ) discloses the information provided herein pursuant to the
Financial Instruments Trading Act and/or the Securities Markets Act. The
information was submitted for publication at 5:30 pm CET on July 31, 2014.